Karyopharm Therapeutics (KPTI) Profit After Tax (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Profit After Tax data on file, last reported at -$102.2 million in Q4 2025.

• Quarterly Profit After Tax fell 232.03% year-over-year to -$102.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$196.0 million (down 156.52% YoY) and the FY2025 annual result came in at -$196.0 million, down 156.52% from the prior year.
• Profit After Tax retreated to -$102.2 million in Q4 2025, from -$33.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $38.7 million in Q4 2021 to a low of -$102.2 million in Q4 2025.
• A 5-year average of -$35.2 million and a median of -$36.8 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2021 — Profit After Tax soared 189.17% — and 2025, when it slumped 256.57%.
• Tracing KPTI's Profit After Tax over 5 years: stood at $38.7 million in 2021, then plunged by 199.45% to -$38.5 million in 2022, then dropped by 8.65% to -$41.8 million in 2023, then gained by 26.43% to -$30.8 million in 2024, then sank by 232.03% to -$102.2 million in 2025.
• The last three Profit After Tax figures came in at -$102.2 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025), per Business Quant data.